SCHEMBL27870

SCHEMBL27870

CN(C)c1ccccc1B(O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.46
GAA P10253 3/20 0.46
ALDH1A1 P00352 2/20 0.46
TSHR P16473 2/20 0.46
TP53 P04637 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ENPP2 Q13822 2/20 0.43
KDM4E B2RXH2 1/20 0.41
LIPG Q9Y5X9 1/20 0.41
CHEK1 O14757 1/20 0.40
NEK2 P51955 1/20 0.40
LIMK1 P53667 1/20 0.40
DYRK1A Q13627 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
EP300 Q09472 1/20 0.39
KAT2B Q92831 1/20 0.39
KAT8 Q9H7Z6 1/20 0.39
ORAI1 Q96D31 1/20 0.37
ORAI2 Q96SN7 1/20 0.37
ORAI3 Q9BRQ5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29589969 1.00 MAPT (0.46) MAPTGAAALDH1A1TSHRTP53
Hydrochloric Acid SCHEMBL29953389 0.98 MAPT (0.45) MAPTGAAALDH1A1TSHRTP53
Hydrochloric Acid SCHEMBL29956265 0.95 MAPT (0.43) MAPTGAAALDH1A1TSHRTP53
SCHEMBL29837163 0.84 ENPP2 (0.39) MAPTGAAALDH1A1TSHRTP53
SCHEMBL20312265 0.80 MAPT (0.41) MAPTGAAALDH1A1TSHRTP53
SCHEMBL30253598 0.78 ENPP2 (0.46) MAPTGAAALDH1A1TSHRTP53
SCHEMBL13299608 0.78 TSHR (0.45) MAPTGAAALDH1A1TSHRTP53
SCHEMBL1580259 0.78 CHEK1 (0.48) MAPTGAAALDH1A1TSHRKDM4E
SCHEMBL3794447 0.78 GAA (0.40) MAPTGAAALDH1A1TSHRTP53
SCHEMBL29276277 0.76 TSPO (0.50) MAPTGAAALDH1A1TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014059586-A1 NOVEL LUMINESCENT MATERIALS EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2014-04-24 WO claimed
EP-4741386-A1 PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2026-05-13 EP disclosed
US-20250388560-A1 AROMATIC COMPOUND AND USE THEREOF HITGEN INC (CN) 2025-12-25 US disclosed
EP-4653421-A1 AROMATIC-RING COMPOUND AND USE THEREOF Hitgen Inc. (CN) 2025-11-26 EP disclosed
US-20250289799-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2025-09-18 US disclosed
EP-4516779-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-03-05 EP disclosed
WO-2025007777-A1 PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 江苏亚虹医药科技股份有限公司 2025-01-09 WO disclosed
US-12187684-B2 Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2025-01-07 US disclosed
US-20240352023-A1 IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SK BIOPHARMACEUTICALS CO., LTD. (KR) 2024-10-24 US disclosed
US-20240327401-A1 FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF Evopoint Biosciences Co., Ltd. (CN) 2024-10-03 US disclosed
WO-2003013430-A2 BENZOQUINONE ANSAMYCINS KOSAN BIOSCIENCES, INC. (US) 2003-02-20 WO disclosed
US-20030009046-A1 Preparation of preparing substituted indanones EQUISTAR CHEMICALS, LP 2003-01-09 US disclosed
WO-2002088274-A1 DOUBLE-SPIRO ORGANIC COMPOUNDS AND ELECTROLUMINESCENT DEVICES LG CHEM, LTD. (KR) 2002-11-07 WO disclosed
EP-1066303-A1 TRANSITION METAL COMPOUND CONTAINING CATIONIC GROUPS WHICH IS USED AS AN OLEFIN POLYMERIZATION CATALYST COMPONENT Basell Polyolefine GmbH (DE) 2001-01-10 EP disclosed
EP-1066330-A1 CATALYST SYSTEM, METHOD FOR THE PRODUCTION THEREOF, AND THE UTILIZATION THEREOF FOR THE POLYMERIZATION OF OLEFINS Basell Polyolefine GmbH (DE) 2001-01-10 EP disclosed
WO-1999050312-A1 CATALYST SYSTEM, METHOD FOR THE PRODUCTION THEREOF, AND THE UTILIZATION THEREOF FOR THE POLYMERIZATION OF OLEFINS TARGOR GMBH (DE) 1999-10-07 WO disclosed
WO-1999050274-A1 TRANSITION METAL COMPOUND CONTAINING CATIONIC GROUPS WHICH IS USED AS AN OLEFIN POLYMERIZATION CATALYST COMPONENT TARGOR GMBH (DE) 1999-10-07 WO disclosed
US-5512246-A Method and means for detecting polyhydroxyl compounds Russell, Anthony P. (US) 1996-04-30 US disclosed
EP-0502955-A1 FLUORINATED SULFONES/KETONES FOR NONLINEAR OPTICS. DU PONT (US) 1992-09-16 EP disclosed
WO-1991008198-A1 FLUORINATED SULFONES/KETONES FOR NONLINEAR OPTICS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327401-A1 FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF SOS1, SOS2, SOST MAPT 3241/4885GAA 2467/4885ALDH1A1 3682/4885
US-20250388560-A1 AROMATIC COMPOUND AND USE THEREOF RNF213, RNF10, TRIM4 MAPT 3041/4885GAA 3800/4885ALDH1A1 3247/4885
US-20240352023-A1 IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME GRM5, GRIK5, GRM1 MAPT 1597/4885GAA 2946/4885ALDH1A1 2901/4885
US-20250289799-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF USP1, UPP1, UFL1 MAPT 1959/4885GAA 589/4885ALDH1A1 336/4885
US-12187684-B2 Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof RORC, RORB, RORA MAPT 3485/4885GAA 715/4885ALDH1A1 244/4885
US-20030009046-A1 Preparation of preparing substituted indanones CYP1A2, CYP1B1, CYP1A1 MAPT 3748/4885GAA 3987/4885ALDH1A1 198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.